Proceedings from the 3rd International Conference on Polymyxins
A special issue of Antibiotics (ISSN 2079-6382).
Deadline for manuscript submissions: closed (31 January 2019) | Viewed by 61756
Special Issue Editors
Interests: antimicrobial resistance, particularly among gram-negative bacilli; optimizing use of polymyxin antimicrobials; prevention of healthcare associated infections including Clostridium difficile, multi-drug resistant organisms, central-line associated infections and surgical site infections; innovative approaches to antimicrobial stewardship
Interests: Dr. Tsuji’s research aims to optimize the exposure-response relationship for a number of antimicrobial agents including colistin, polymyxin B, vancomycin, and beta-lactams against clinically challenging pathogens. His ongoing projects explore novel pharmacokinetic/pharmacodynamic approaches for polymyxin combinations against multidrug resistant Acinetobacter baumannii, Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa
Interests: Dr. Bulman’s laboratory investigates innovative polymyxin-based combination treatment strategies to combat carbapenem-resistant Enterobacteriaceae. He is also interested in understanding the relationship between polymyxin resistance and bacterial virulence. His current projects aim to target antimicrobial therapies to the infecting pathogen in an attempt to understand bacterial contributions to resistance and treatment failure
Interests: Dr. Lenhard’s research endeavors focus on the rational design and optimization of polymyxin combinations against carbapenem-resistant and polymyxin-resistant A. baumannii. Ongoing investigations seek to identify optimal antibacterial regimens in the face of polymicrobial infections characterized by bacterial cooperation and modulated antimicrobial activity
Special Issue Information
Dear Colleagues,
The polymyxin antibiotics (polymyxin E (colistin) and polymyxin B) have seen a recent resurgence in clinical use due to the sharp rise in infections caused by multidrug-resistant Gram-negative pathogens that are not susceptible to most antimicrobial agents. This important role, as a last-line antibiotic, has recently led the World Health Organization to add the polymyxins to their “Highest Priority” tier of critically important antimicrobials for human medicine. However, since the polymyxins became available in the 1950s when there was substantially less regulatory rigor needed for drug approval than today, significant opportunity and need remains to optimize the use of polymyxins to improve patient care.
The International Conference on Polymyxins is a gathering of the world’s leading opinion-leaders to discuss the cutting-edge of polymyxin research and clinical use. Recently, the 3rd iteration of this conference occurred from April 25–26, 2018, in Madrid, Spain. Over 30 presentations by world leaders were provided to: highlight recent accomplishments in the field, deliver updates on toxicity, describe advances in the use of polymyxin-based combinations, summarize regulatory and world health perspectives of polymyxin use, discuss recent discoveries in polymyxin resistance, provide updates regarding susceptibility testing, project the future role of polymyxins, and provide a roadmap for future research.
In this Antibiotics Special Issue, we aim to highlight the proceedings from the 3rd International Conference on Polymyxins. We have procured a collection of articles from the perspectives of the world’s leading experts that review recent advances in polymyxin research and clinical use and provide an overview of the conference. In addition to providing highlights from the conference, articles also speculate on the future of polymyxin research and novel approaches to polymyxin therapy in the clinic. Through this 3rd International Conference on Polymyxins Special Issue, we hope to both reflect on, as well as stimulate, constructive discussion and research regarding the polymyxins so that this important antimicrobial class can be best used to benefit patients in need for many years to come.
Sincerely,
Dr. Keith S. Kaye
Dr. Brian T. Tsuji
Dr. Zackery P. Bulman
Dr. Justin R. Lenhard
Guest Editors
Conference Website:
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.